Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas

Pediatr Blood Cancer. 2019 Apr;66(4):e27579. doi: 10.1002/pbc.27579. Epub 2018 Dec 11.

Abstract

One of the limitations of performing percutaneous biopsies in patients with bone sarcomas is the small amount of tumor that can be obtained for research purposes. Here, we describe our experience developing patient-derived tumor xenografts (PDXs) using percutaneous tumor biopsies in children with bone sarcomas. We generated 14 bone sarcoma PDXs from percutaneous tumor biopsies. We also developed eight bone sarcoma PDXs from surgical resection of primary bone tumors and pulmonary metastases. A multidisciplinary team approach was critical to establish an accurate diagnosis and to provide adequate tumor samples for PDX generation.

Keywords: ewing sarcoma; osteosarcoma; patient-derived tumor xenograft; percutaneous biopsies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Neoplasms* / metabolism
  • Bone Neoplasms* / pathology
  • Bone Neoplasms* / therapy
  • Child
  • Female
  • Humans
  • Lung Neoplasms* / metabolism
  • Lung Neoplasms* / pathology
  • Lung Neoplasms* / secondary
  • Lung Neoplasms* / therapy
  • Male
  • Neoplasm Metastasis
  • Osteosarcoma* / metabolism
  • Osteosarcoma* / pathology
  • Osteosarcoma* / therapy
  • Xenograft Model Antitumor Assays